For manufacturers planning clinical investigations or IVD performance studies across multiple EU Member States, a long-standing pain point has been clear: separate submissions to each competent authority, independent reviews, inconsistent national interpretations, duplicated documentation, heavy communication workloads and unpredictable timelines. To address these challenges, the EU has launched the CI/PS Coordinated Assessment Pilot (Pilot coordinated assessment for Clinical Investigations / Performance Studies) under Article 78 of the MDR and Article 74 of the IVDR. Sponsors only need to submit one single application to join a joint multi-country review, which substantially cuts administrative burdens for cross-border clinical programmes.This pilot also serves as a preparatory exercise for the upcoming mandatory EU coordinated assessment framework. Sponsors participating in the pilot will help the European Commission build and validate this future mandatory system, as amended by Regulation (EU) 2024/1860.
https://health.ec.europa.eu/medical-devices-clinical-investigations-and-performance-studies/pilot-coordinated-assessment-cips_en
Faster overall approval:The coordinated workflow supports competent authorities to issue national decisions more quickly.
The MDCG Working Group on Clinical Investigations and Evaluations reviews expressions of interest on a rolling basis. Two core evaluation criteria apply:
After review, selected sponsors will receive formal notification together with a full resource package, including SOPs, guidance materials and templates. Selected sponsors have a two-week window to raise questions and arrange bilateral clarification meetings with the Secretariat and participating authorities.
Reference Documents for Submission: